SEATTLE, WA--(Marketwire - March 14, 2011) -
Atossa Genetics, Inc., a privately-held health care company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer, announced today that Steven C. Quay, M.D., Ph.D., Chairman, President and CEO, has been elected as a Fellow of the College of American Pathologists (FCAP).
The College of American Pathologists (CAP) is the leading organization of board-certified pathologists, serving approximately 17,000 physician members and the laboratory community to foster and advocate for excellence in the practice of pathology and laboratory medicine.
"I am honored to have been elected as a Fellow of the College of American Pathologists, a world-renowned medical society known for its industry leadership in laboratory quality assurance and strong advocacy for high-quality, cost-effective medical care," commented Dr. Quay. "I look forward to working with the CAP to advance the interests of the pathology community and patients."
About Steven C. Quay, M.D., Ph.D.
Dr. Quay is Chairman, President and CEO of Atossa Genetics, Inc., a privately held health care company that has developed and is commercializing the Mammary Aspirate Specimen Cytology Test System (MASCT System), a new, patented, FDA-cleared breast cancer risk assessment test. Dr. Quay is a named inventor on 14 U.S. and foreign patents covering the MASCT System.
A physician, scientist, and biotechnology entrepreneur, Dr. Quay has founded six companies and rebranded a seventh during a more than 25-year career. He has invented five drugs, as well as the MASCT System, which have been approved by the FDA, and has received 69 U.S. patents.
He is certified in Anatomic Pathology with the American Board of Pathology, is a Fellow of the College of American Pathologists, and is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening, and the Association of Pathology Informatics.
Dr. Quay completed an internship and residency in anatomic pathology at the Massachusetts General Hospital, a Harvard Medical School teaching hospital. He is a former faculty member of the Department of Pathology, Stanford University School of Medicine.
Dr. Quay has received a number of prestigious awards over the course of his career including Ernst & Young's 1997 Entrepreneur of the Year. In February 2011, he was recognized by Seattle Business magazine as one of the top healthcare leaders in the Pacific Northwest.
About the Mammary Aspirate Specimen Cytology Test System
The MASCT System, a "Pap test for breast cancer," is designed to collect nipple aspirate fluid (NAF), which contains cells from the lining of the milk ducts and the lobules where approximately 85% of all breast cancers originate. Once collected, the NAF sample will undergo analysis in Atossa's specially equipped pathology lab to determine whether the cells are normal, atypical (premalignant), or malignant. The MASCT System uses no radiation, is simple, painless, and inexpensive, and takes less than 5 minutes in a doctor's office or mammography center. The MASCT System is intended as an adjunct to mammography for women ages 40 to 75 and for younger women at high risk for breast cancer.
The MASCT System is expected to be launched in the Pacific Northwest this year and across the U.S. in 2012.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. is a privately held health care company dedicated to improving breast health by commercializing the Mammary Aspirate Specimen Cytology Test System (MASCT System and second-generation products in development. Patients, health care providers, investors and others seeking information on the MASCT System or the latest information and research on breast cancer risk assessment, diagnostics, prevention, and treatment options, should visit www.atossagenetics.com.